Nuformix PLC (LSE:NFX) has taken a step closer to generating a ‘robust data package’ for its lead asset, NXP002.
A new form of tranilast, an asthma treatment, the drug is being developed to combat idiopathic pulmonary fibrosis, a form of scarring of the lung.
Nuformix on Wednesday said it has now completed pre-clinical tolerability studies over a new range of doses, some of which were higher than previously administered.
The medication was delivered using an unnamed ‘alternative method’ designed to ensure consistent and controlled inhalation.
The company has now begun to explore how the new doses studied can ‘best optimise efficacy and confirm NXP002's positive pharmacological profile’.
“The results from this first stage are exactly what we had hoped for and bode well for the inhaled tolerability of NXP002, even at high doses,” said Nuformix director, Dr Daniel Gooding.
“We are pleased that we can now progress to robustly investigate NXP002's efficacy as we continue to build a pre-clinical data package to support the further progression of the Company's lead programme.”